Vergleich von Trastuzumab-Biosimilar ABP 980 mit Referenz-Trastuzumab bei der neoadjuvanten Therapie von HER2-positivem Brustkrebs – Analyse eines großen universitären Brustkrebsz…
Sabine Matovina, Tobias Engler, Lea Louise Volmer, Heike Müller, Eva-Maria Grischke, Annette Staebler, Markus Hahn, Sara Yvonne Brucker, Andreas Daniel Hartkopf · Senologie - Zeitschrift für Mammadiagnostik und -therapie · 2024 · Heft 02 · S. 132-139
Bibliografische Angaben
Zusammenfassung
Abstract Background ABP 980 is a biosimilar antibody to reference trastuzumab (RTZ). Aim of the following study is to confirm the similarity of ABP 980 and RTZ in terms of clinical efficacy and safety in patients with HER2-positive early breast cancer (EBC) undergoing neoadjuvant trastuzumab-containing chemotherapy in a clinical real-world situation that also includes patients receiving pertuzumab. Methods Patients with HER2-positive EBC, who were treated from 12/2010 to 03/2020 at the Department of Women’s Health at Tuebingen University Hospital, Germany, with at least four cycles of neoadjuvant chemotherapy (+…
